Management of pasireotide-induced hyperglycemia in patients with acromegaly: An experts' consensus statement.

"Conflict of interest SS has received consulting fees from Crinetics and Recordati Rare Diseases RRD as well as honoraria for lectures and conference chairing from Novartis, Ipsen, Hexal/Sandoz, Pfizer, and RRD. He has served as advisory board member for Novartis and RRD. Furthermore, RRD has donated a drug for compassionate use in one of his patients. SM has received lecturing fees and/or consulting fees and/or grants from AstraZeneca, Bayer, Boehringer Ingelheim, Lilly, Novo Nordisk, RRD. JG and JF have received consulting fees from RRD. KS has received lecturing fees and/or consulting fees from Pfizer, RRD, Sandoz, and Novo Nordisk. JS has received honoraria for talks and/or consultancy and/or research funding from Apitope, AstraZeneca, Bayer, Berlin Chemie, Boehringer Ingelheim, Bristol-Meyers Squibb, Eli Lilly, GI-Dynamics, GlaxoSmithKline, Intarcia, Ipsen, Janssen, LifeScan, MedScape, MSD, Novartis, Novo Nordisk, Omniamed, Pfizer, RRD, Roche, Sanofi, Servier, Takeda, and Ypsomed. In the past 3 years BV has received honoraria from Amgen, AstraZeneca, Lilly, Novo Nordisk, Sanofi and RRD for conferences or advisory boards, and received funding for research from AstraZeneca and Novo Nordisk."

"The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research project received support from Recordati Rare Diseases (RRD), providing sponsorship for the meetings including covering costs for the venue, participant travel, and food services. Furthermore, RRD funded editorial assistance by a professional medical writer. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication."